Maternal pertussis immunization and the blunting of routine vaccine effectiveness: A meta-analysis and modeling study

Author list:

Michael Briga[a], PhD,

Elizabeth Goult[a], MSc,

Tobias S Brett[b,c], PhD,

Pejman Rohani[b,c,d], PhD, Prof.,

Matthieu Domenech de Cellès[a], PhD

Affiliations:

[a]Infectious Disease Epidemiology Group, Max Planck Institute for Infection Biology, Berlin, Germany

[b]Odum School of Ecology, University of Georgia, Athens, GA 30602

[c]Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602

[d]Center of Ecology of Infectious Diseases, University of Georgia, Athens, GA 30602

Corresponding author:

Michael Briga: michbriga@gmail.com

Abstract

A key goal of pertussis control is to protect infants too young to be vaccinated, the age group most vulnerable to this highly contagious respiratory infection. In the last decade, maternal immunization has been deployed in many countries, successfully reducing pertussis in this age group. Because of immunological blunting, however, this strategy may erode the effectiveness of primary vaccination at later ages. Here, we systematically reviewed the literature on the relative risk (RR) of pertussis after primary immunization of infants born to vaccinated vs. unvaccinated mothers. The four studies identified had ≤6 years of follow-up and large statistical uncertainty (meta-analysis weighted mean RR: 0.71, 95% CI: 0.38–1.32). To interpret this evidence, we designed a new mathematical model with explicit blunting mechanisms and evaluated maternal immunization's short- and long-term impact on pertussis transmission dynamics. We show that transient dynamics can mask blunting for at least a decade after rolling out maternal immunization. Hence, the current epidemiological evidence may be insufficient to rule out modest reductions in the effectiveness of primary vaccination. Irrespective of this potential collateral cost, we predict that maternal immunization will remain effective at protecting unvaccinated newborns, supporting current public health recommendations.

Introduction

Pertussis is a highly transmissible respiratory infection that is primarily caused by the bacterium *Bordetella pertussis*[1,2]. Pertussis was a leading cause of childhood mortality until intense immunization programs, from the 1940s onwards, reduced pertussis notifications by over 90% in many countries[3,4]. However, in the last couple of decades, pertussis has re-emerged in many populations with high long-term immunization coverage, for reasons which remain highly debated[5].

Newborns are the age group most vulnerable to pertussis. In high-income countries, pertussis-related hospitalization rates in infants under 6 months are between 100 and 100,000 per year[6], and data from the US[7] and Australia[8] show that over 60% of pertussis-associated hospitalizations are under one year old. To reduce the burden of pertussis in vulnerable newborns, since 2012, many countries have introduced maternal immunization—*i.e.*, vaccinating pregnant individuals, usually during the second or third trimester of pregnancy, with a low-dose tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine. In 2015, the World Health Organization (WHO) issued an official recommendation for maternal immunization with acellular vaccines against pertussis (based on studies with acellular primary immunization)[9], and by 2020 maternal immunization against pertussis was recommended in 55 countries[10].

Maternal immunization is highly effective at protecting newborns, with estimates of reductions in the risk of pertussis infection ranging from 70 to 95%[8,11–17]. However, the downstream consequences of maternal immunization, when infants receive their routine pertussis vaccines, are poorly understood. Specifically, there has been long-standing concern regarding potential immunological blunting, *i.e.*, the interference of maternally transferred antibodies with the infant immune response[18–20]. Indeed, several studies and meta-analyses have shown that, after infants received their primary immunization, the antibody concentrations against several pertussis antigens were reduced by 30% to 60% in infants from vaccinated mothers relative to infants from unvaccinated mothers[21–24]. Similarly, the avidity of pertussis antibodies is reduced in infants from vaccinated mothers[25]. Interestingly, the blunting response following maternal pertussis immunization appears to be heterologous, also causing decreased

antibody concentration after infants received a polio vaccine[26] and the blunting response also applies to other vaccines that contain (modified) diphtheria or tetanus toxins as carrier proteins, such as pneumococcus conjugate vaccines[22,26].

While immunological blunting is well documented, because the first maternal immunization programs were implemented in 2012, the long-term consequences of blunting on vaccine effectiveness (VE) and the ensuing epidemiology of pertussis remain difficult to evaluate. Here, we assess the epidemiological evidence for blunting and estimate the long-term consequences of maternal immunization in three steps. First, we perform a systematic review of the literature for estimates of the impact of maternal immunization on the relative risk of pertussis after primary pertussis immunization in infants from vaccinated mothers relative to unvaccinated mothers. Second, we extend a previously validated model of pertussis immunization[4,27] to simulate over several decades the short- and long-term epidemiological impact of maternal immunization with various levels of blunting and maternal immunization coverages on the age-specific time series of pertussis incidence. Third, to identify possible levels of blunting and the consequences of maternal immunization, we match the relative risk estimates obtained from the systematic review with those obtained from the modeling study.

Results

A systematic review of empirical studies on the relative risk of pertussis after maternal and infant primary immunization

We identified 374 peer-reviewed articles and, after removing 146 duplicate records, we screened 228 abstracts for a mention of maternal immunization with either a number of cases, an odds ratio or a relative risk of pertussis and/or effectiveness of a pertussis vaccine (Fig. 1). Based on these criteria, we identified and retrieved 69 articles that might contain information (Table S4).

Our search identified four studies that reported five estimates of the relative risk of pertussis in infants from vaccinated versus unvaccinated mothers and that specified the

105 dose of infant primary immunization (Fig. 1, Fig. 2, Table S1). Two studies were carried
106 out in the UK, one in Australia, and one in California, US. In all studies, maternal
107 immunization coverage was low right after the implementation of maternal
108 immunization but increased to reach >70% (Table S1). The studies' follow-up times
109 ranged from 2 to 6 years (Table S1). At the first dose of infant primary immunization,
110 these studies showed a weighted mean RR of 0.26 (Fig. 2, 95% CI: 0.11–0.67). At the
111 second dose of infant primary immunization, the RR increased to a weighted mean of
112 0.73 (Fig. 2, 95% CI: 0.39–1.34) and this was very similar to the weighted mean RR at
113 the third dose of infant primary immunization which had a value of 0.71 (Fig. 2, 95% CI:
114 0.38–1.32).
115
116 *The model recapitulates the historical trends of pertussis, with a resurgence caused by a*
117 *honeymoon effect*
118
119 To interpret the RR estimates and assess the short- and long-term impact of blunting on
120 pertussis transmission dynamics, we extended an empirically validated model of
121 pertussis epidemiology[4,27], to incorporate maternal immunization and its dual effects of
122 protecting unvaccinated newborns and blunting vaccine effectiveness after infant
123 primary immunization. To assess the historical impact of routine immunization in
124 infants, we first examined the trends in overall incidence and age-specific susceptibility.
125 Infant immunization induced a strong decrease in pertussis incidence but was followed
126 by a rebound with a gradual buildup of susceptible individuals in adult age groups until
127 a new equilibrium—with lower incidence than in the pre-vaccine era—was reached
128 several decades later (Fig. 3 A & B). As previously demonstrated in the US, this
129 resurgence was explained as an "end-of-honeymoon" effect, a predictable consequence
130 of incomplete immunization with imperfect but highly effective vaccines. Hence, our
131 model recapitulated the historical dynamics of pertussis in the US, characterized by a
132 resurgence and shift of infections to adolescent and adult age groups[4].
133
134 *Transient dynamics after the start of maternal immunization*
135
136 Second, we examined the impact of maternal immunization, which we introduced 100
137 years after the rollout of infant immunization, to disentangle the consequences of the

138 two immunization programs. Maternal immunization had the intended effect of
139 decreasing susceptibility to infection in unvaccinated newborns aged 0–2 months
140 (Fig. 3B). However, after the rollout of maternal immunization, the model predicted a
141 transient phase with lower pertussis incidence, lasting at least 5 years and followed by a
142 rebound (Fig. 4A). In newborns, pertussis incidence was lower after the start of
143 maternal immunization relative to before, but the benefit of maternal immunization was
144 larger in a scenario without blunting than in a scenario with blunting (Fig. 4A). Thus,
145 maternal immunization was predicted to be effective at protecting unvaccinated
146 newborns, with benefits by far outweighing any possible blunting-mediated increases in
147 incidence.
148
149 By contrast, in the second age class of infants aged 3–18 months, (*i.e.*, after receipt of the
150 primary pertussis immunization), maternal immunization was followed by a decrease of
151 pertussis incidence, but only when blunting was low (<10%, Fig. 4B). At higher levels of
152 blunting, pertussis incidence was predicted to increase relative to before the start of
153 maternal immunization (Fig. 4B). Irrespective of the simulated blunting level, the
154 second age class also showed a clear transient phase, lasting at least 5 years (Fig. 4B).
155 During this transient phase, pertussis incidence was first predominantly driven by
156 infants from unvaccinated mothers (Fig. 4C), followed later on by incidence in infants
157 from vaccinated mothers, who dominated once incidence had reached equilibrium (Fig.
158 4D). These dynamics persisted in children up to 5 years of age, but dissipated by age 10
159 years, after which pertussis incidence remained low and the effects of both maternal
160 immunization and blunting on pertussis incidence were negligible (Fig. S3).
161
162 *Comparison with empirical estimates suggests that blunting cannot be ruled out*
163
164 Lastly, we estimated the impact of blunting on the RR of pertussis in vaccinated infants
165 born to mothers vaccinated during pregnancy. In newborns, our simulations show that
166 estimates of the effectiveness of maternal immunization (*i.e.*, based on incidence) have a
167 transient phase in a direction consistent with those deduced from the transient
168 incidence dynamics: the effectiveness of maternal immunization was high at first but
169 decreased with time, and equilibrium values were reached only after a transient phase
170 that lasted at least a decade (Fig. 5A). Hence, ignoring the transient dynamics results in

171 an overestimation of the effectiveness of maternal immunization, an effect most
172 pronounced during the first decade after implementation.
173
174 As expected, in the second age class of infants aged 3–18 months, (*i.e.*, after receipt of
175 the primary pertussis immunization), blunting resulted in RR equilibrium values above
176 1 (*i.e.*, a higher risk of pertussis in infants born to vaccinated mothers relative to
177 unvaccinated mothers), which increased with the input blunting strength. However,
178 these risks were reached only after a transient phase that lasted more than a decade
179 (Fig. 5B). During this transient phase, even in scenarios with blunting, the RR was
180 initially far below 1 and gradually increased after the start of maternal immunization.
181 Hence, ignoring these transient dynamics and assuming that an RR of 1 indicates no
182 blunting may result in overestimating the effectiveness of maternal immunization in
183 both unvaccinated newborns and vaccinated infants (Fig. 5B). It is noteworthy that the
184 transient phase for the estimation of RR (Fig. 5 A & B) is longer than for the incidence
185 (Fig. 4 A & B). This is because RR (and hence VE) are cumulative estimates instead of
186 instantaneous estimates such as incidence (Fig. S4). Interestingly, depending on the
187 contact matrix, the incidence during the transient phase showed oscillating dynamics,
188 which increases the variability between estimates after 3, 6, or even 10 years (Figs. S12,
189 S13), but these oscillations disappeared in the RR estimates (Figs. S14, S15), likely
190 thanks to their cumulative nature. Interestingly, after the transient phase, a scenario
191 without blunting resulted in RRs below 1, due to residual protection from maternal
192 antibodies in infants who were vaccinated but in whom the vaccine did not take. This
193 result suggests that the usual assumption that an RR of 1 indicates no blunting may be
194 too optimistic.
195
196 Comparing our model predictions with the results of epidemiological studies, all current
197 empirical RR estimates fell well within the transient phase of our simulations (Fig. 5C).
198 Demographic stochasticity accounted for some of the variability in the predicted RR
199 (Fig. 5B), but observation noise due to small sample sizes was by far the largest source
200 of uncertainty (Fig. 5C). Inspecting the overlap between confidence intervals, all the
201 empirical estimates were consistent with blunting, even though two estimates (in the
202 UK and California) were also consistent with no blunting. Hence, according to our
203 simulations, current empirical studies cannot yet detect the eventual epidemiological

204 consequences of blunting (Fig. 5B), because of the transient RR dynamics following the
205 rollout of maternal immunization. Hence, the model-data comparison suggests that
206 current empirical RR estimates cannot rule out a modest level of blunting of infant
207 primary immunization (Fig. 5C).
208
209 *Sensitivity analyses*
210
211 To assess the robustness of our results, we conducted a range of sensitivity analyses
212 with different hypotheses regarding model parameters, such as the coverage of
213 maternal and infant immunization, the average duration of maternal protection, age-
214 specific contact patterns, the age of primary immunization, and the basic reproduction
215 number). To assess the consequences of non-pharmaceutical interventions (NPIs)
216 during the COVID-19 pandemic, we further simulated scenarios with transient
217 reductions in vaccine coverage and pertussis transmission. In our simulations,
218 variation in these parameters sometimes had a substantial impact on pertussis
219 incidence, e.g., Figs. S7, S9, S11, and S13. However, our conclusions about blunting were
220 robust in all the sensitivity analyses, and the results presented in Figs. S5 to S34 were
221 consistent with those presented in Fig. 4 and Fig. 5.
222
223 The sensitivity analyses revealed a few noteworthy results. First, a considerable
224 reduction of the blunting effect on pertussis incidence was predicted when delaying the
225 age at the start of the infant's primary immunization by a few months (Fig. S11, S12).
226 Second, the empirical epidemiological studies with two or three years of monitoring
227 could match scenarios with blunting reducing vaccine effectiveness by up to 50% (Fig.
228 S22). However, such a high level of blunting could be ruled out by the 6-year study in
229 the UK. This indicates the need for larger sample sizes and longer monitoring to reliably
230 estimate vaccine effectiveness and the impact of new immunization programs. Third,
231 consistent with expectation and epidemiological observations, the COVID-19 pandemic
232 was predicted to have a substantial impact on pertussis dynamics, with a decline in
233 incidence followed by a rebound (e.g., Figs. S25 A&B, S27A&B, S29A&B, S31A&B, S34 A-
234 D). However, the temporal dynamics of RR remained consistent in this scenario (Figs.
235 S32, S33, S34 E-H), likely because in our model control measures equally affected
236 infants born from vaccinated or unvaccinated mothers.

Discussion

In this study, we aimed to review the epidemiological evidence regarding the impact of maternal immunization on the effectiveness of pertussis vaccines in infants. We interpret this evidence using a new mechanistic mathematical model that represented the effect of blunting on pertussis transmission dynamics. Our systematic review identified four observational epidemiological studies, which had a maximum monitoring time of 6 years and were often combined with small sample sizes. Most studies suggested a reduced risk of pertussis after receipt of the first vaccine dose in infants born to mothers immunized during pregnancy. After receipt of the second or third vaccine dose, however, the estimates had large uncertainty, consistent with a range of assumptions about blunting levels. To interpret these empirical estimates, we performed a simulation study using an age-structured model of pertussis transmission. This model predicted that the introduction of maternal immunization was followed by a transient phase lasting at least a decade, during which the blunting effect of maternal antibodies could be underestimated. The model-data comparison suggested that a modest level of blunting could not be ruled out, even though the large uncertainty in empirical estimates prevented a definitive conclusion. Even in the presence of such blunting, however, our model predicted that maternal immunization remained effective at reducing pertussis in unvaccinated newborns. Hence, our results confirm that maternal immunization is an effective strategy to protect this age group, but suggest it may eventually result in an infection-control trade-off with older age groups.

Unvaccinated newborns are the age group most vulnerable to pertussis, both in terms of infection and hospitalization risks[6,7,8]. Our study suggests that, although blunting may erode the benefits of immunization in infants, maternal immunization is highly effective at protecting unvaccinated newborns. Hence, our results support the decision of many public health authorities to introduce maternal immunization against pertussis, provided that the main control objective is to protect newborns[9,10]. More generally, given the vulnerability of newborns to many pathogens, maternal immunization against other infectious diseases is considered by public health authorities, and the pharmaceutical industry is developing new vaccines for immunization during

270 pregnancy. For example, a maternal vaccine against RSV recently underwent successful
271 phase 3 trial[28] and may soon be rolled out[29]. In addition to the Tdap and RSV vaccines,
272 maternal immunization is implemented or recommended for influenza, COVID-19, and
273 several other infections[30–32]. Maternal immunization, therefore, also appears as a
274 promising strategy to protect newborns against these infections, but given that
275 immunological blunting has been documented for many infections[18,33–36], our results
276 suggest the need to monitor its impact on subsequent vaccination of infants carefully.
277
278 One of the main takeaways from our review was the large uncertainty around the
279 available empirical estimates, emphasizing the urgent need for more research on
280 blunting. However, if such blunting is confirmed by future evidence, there are ways to
281 mitigate its impact. Immunity in newborns conferred by maternal antibodies against
282 pertussis likely wanes quickly, on a timescale of months, according to our model. Given
283 the fast waning of maternal antibodies and the association between the maternal
284 antibody titers and the blunting of infant immune responses[37], delaying infant primary
285 immunization by a few months might greatly reduce the maternal blunting of infant
286 immunization[35]. Pertussis immunization schedules vary greatly between countries, with
287 the age at first immunization of infants typically ranging between two and four
288 months[38], and the current variation in pertussis immunization schedule can
289 significantly impact the effectiveness of pertussis immunization in infants[39]. If maternal
290 blunting occurs, our results suggest that the optimal age at first immunization is
291 governed by a trade-off between vaccinating too early (with the effect of reducing the
292 susceptibility age window in newborns but amplifying the impact of blunting in
293 vaccinated infants) and too late (with the opposite effect). As the costs of infection in
294 unvaccinated newborns likely exceed those in older age groups, the introduction of
295 maternal immunization may thus increase the optimal age at first immunization, in all
296 infants or only in those born to vaccinated mothers. The Dutch public health authorities
297 take an interesting approach: the recommended age for the first dose of primary
298 immunization for children from unvaccinated mothers is two months, while for children
299 from vaccinated mothers, the recommendation is to start one month later, at three
300 months[40]. Identifying the optimal pertussis immunization schedule for infants would be
301 helpful for public health authorities, especially given the vast between-country variation

302 in pertussis immunization schedules[38,39,41]. Our new model could thus help future
303 research on optimal vaccine schedules.
304
305 After the roll-out of maternal immunization, our model predicted a transient phase
306 lasting approximately a decade, during which the incidence of pertussis—in both
307 unvaccinated newborns and vaccinated infants—initially dropped, but then bounced
308 back and increased to reach a new equilibrium. The duration of this transient phase is
309 consistent with that found in a previous modeling study[42] and may be explained by the
310 time required for the first cohorts of blunted-vaccinated infants (*i.e.*, born to vaccinated
311 mothers) to reach primary school age and its associated high contacts. Thus, reduced
312 transmission from unvaccinated newborns may explain the initial decrease in incidence
313 across age groups, but this benefit gradually wears off as blunted-vaccinated, and
314 therefore less well-protected, children age.
315
316 From a practical perspective, the transient phase following maternal immunization has
317 at least two important implications. First, the current individual-based epidemiological
318 studies had ≤6 years of monitoring, which we predict is insufficient to capture the
319 consequences of maternal immunization that can only be detected with at least a decade
320 of data. Second, an RR of 1 is considered the baseline value indicating that maternal
321 immunization does not blunt vaccine effectiveness in infants. In the transient phase,
322 however, our model predicts that the baseline value under a no-blunting scenario starts
323 off close to 0 and gradually increases to an equilibrium just below 1. This equilibrium
324 value results from the residual protection from maternal antibodies, which partially
325 compensates for failures of primary immunization in infants born to vaccinated
326 mothers. These results suggest that the early empirical estimates of vaccine
327 effectiveness may overestimate the benefits of maternal immunization, both for
328 newborns and for infants. A testable prediction of our model, therefore, is that the
329 benefits of maternal immunization estimated in subsequent studies will be lower than
330 those currently reported, both in newborns and after the primary series. More broadly,
331 as reflected in some official guidelines for vaccine impact evaluation[43] and
332 demonstrated for other vaccines such as influenza and streptococcus, biased estimation
333 of vaccine effectiveness because of transient dynamics early after vaccine rollout is
334 likely a more general occurrence.

335

336 Epidemiological monitoring studies have, until now, not reported maternal
337 immunization-mediated rebounds in pertussis incidence (e.g.,[44]). However, we believe
338 that the best way to quantify the clinical and epidemiological impact of blunting is by
339 more precise individual-level estimation of the RR (ideally after the transient phase
340 predicted by our model), instead of monitoring population-level changes in pertussis
341 incidence. This is for several reasons. First, we predict that the rebound a few years
342 after the roll-out of maternal immunization will be small compared to the large
343 reduction immediately after. Hence, detecting an increase in pertussis incidence
344 resulting from maternal immunization may be difficult. Second, many countries have
345 reported pertussis resurgence in the last decades[5], so empirical studies of pertussis
346 incidence may face the challenge of disentangling pre-maternal immunization increases
347 from a post-maternal immunization rebound, which is challenging especially
348 considering the multiannual periodicity of pertussis. The interpretation of trends in
349 pertussis incidence may be further compounded by changes in national immunization
350 schedules (e.g.,[39]) and the impact of NPIs during the COVID-19 pandemic. For the latter,
351 we predict that the RR will remain a more robust metric.

352

353 In addition to the monitoring time, other components of the design of current
354 epidemiological studies may affect their interpretation. First, as the mothers' decision to
355 receive Tdap during pregnancy is voluntary and likely related to other socioeconomic
356 factors that will affect—and presumably reduce—their infants' risk of pertussis, the
357 baseline comparability between groups in these observational studies is far from
358 obvious. Hence, estimates of the effectiveness of maternal immunization may have been
359 confounded by healthy user bias; interestingly, the study that controlled most
360 thoroughly for maternal characteristics[16] had large statistical uncertainty around its RR
361 estimates and could not rule out blunting. In addition to this confounding problem,
362 maternal immunization may prevent mothers from transmitting pertussis to their
363 infants, an indirect effect that could lead to underestimating the risk of pertussis and
364 masking the effect of blunting in the group of infants vaccinated and born to vaccinated
365 mothers (as recognized by some investigators[13]). Because of these potential biases,
366 current RR estimates may have been underestimated. Our model does not account for

367 such potential biases, and hence, our model predictions regarding the level of blunting
368 may be conservative.
369
370 Our study has several limitations. First, our model was parameterized based on
371 previous estimates in Massachusetts, USA, and may only correctly represent pertussis
372 epidemiology in comparable high-income countries. To address this limitation, we have
373 performed sensitivity analyses with a range of basic reproduction numbers, and the
374 conclusions were consistent. Second, in the absence of serological correlates of
375 protection for pertussis[45-47], the duration of maternally-derived protection—and in
376 particular how it connects to maternal antibody titers in the infant—is unknown. In our
377 model, this parameter was calibrated to reach empirical estimates of maternal
378 immunization effectiveness in newborns, with an average duration of maternally
379 derived protection at 8.7 months resulting in vaccine effectiveness for newborns close
380 to 80%. Even though sensitivity analyses demonstrated that our main results were
381 robust to variations in this parameter, more accurate estimation will be important to
382 inform future models and to predict optimal vaccination schedules. Third, for simplicity,
383 we did not model the direct, protective effect of maternal immunization on mothers—
384 only the indirect effect on their newborns. This direct effect is an additional benefit of
385 maternal immunization, but because in high-income countries the proportion of women
386 giving birth is small relative to the total adult population (the 2010–2021 EU average
387 ranging between 1.50 and 1.57 live births per 1,000 individuals and the range among all
388 EU-member states in 2021 between 1.1 and 1.8 live births per 1,000 individuals[48]), it is
389 expected to have a minor epidemiological impact. Fourth, in our simulations, maternal
390 immunization coverage was fixed at 70%, while in real-world settings it is often initially
391 low and takes several years to increase to the higher values described in Table S1 (e.g.,
392 Fig. 1 in[14]). However, such temporal variations in immunization coverage are expected
393 to increase the duration of the transient phase and would thus reinforce our
394 conclusions about the unreliability of early empirical estimates.
395
396 To conclude, our study shows that maternal immunization is effective at protecting
397 newborns, even when blunting erodes some of its benefits. The degree of blunting and
398 the extent to which it entails an epidemiological cost in older age groups can not be
399 known yet, as we predict that the implementation of maternal immunization is followed

400 by a transient phase during which the epidemiological impact of blunting is masked.
401 Hence, current epidemiological studies may be insufficient to rule out blunting or grasp
402 the long-term epidemiological consequences of maternal immunization. Our results,
403 therefore, identify the need for more research to precisely estimate the degree of
404 blunting after primary immunization, if any. More generally, our study supports the use
405 of maternal immunization to reduce pertussis in newborns, but suggests this strategy
406 may be associated with an infection-control trade-off between different age groups.
407
408 **Methods**
409
410 *Systematic review and meta-analysis of empirical studies on the relative risk of pertussis*
411 *after maternal and infant primary immunization*
412
413 We searched the literature on Web of Science, PubMed, and Scopus on August 25, 2023.
414 We used the search terms "maternal immunization AND pertussis AND effectiveness OR
415 maternal vaccination AND pertussis AND effectiveness". In Web of Science, we entered
416 these terms under 'Topic', in PubMed we entered these terms under 'Title/Abstract',
417 and in Scopus under 'Article type, Abstract, Keywords'. In these three searches, we
418 selected the publication dates from January 1, 2012, which is the first complete year
419 with recommended maternal immunization in any country[14], until August 25, 2023. To
420 be included in our review, studies had to provide an estimate of the relative risk (RR) of
421 pertussis in infants having received at least one dose of their primary immunization
422 from vaccinated vs. unvaccinated mothers. We selected only those studies that used
423 laboratory-confirmed diagnosis of pertussis. Because the RR of pertussis varies
424 substantially between doses of infant primary immunization, we selected only studies
425 that were explicit about the number of doses of primary immunization and we excluded
426 those studies that pooled estimates for various doses. For studies that provided more
427 than one estimate per dose, we used all estimates provided. When studies provided
428 estimates with and without known pertussis onset dates, we chose those estimates with
429 known onset dates.
430
431 To estimate the RR per dose of infant primary immunization, we performed the
432 analyses in two ways, which gave consistent results. First, we estimated the weighted

433 means of RR per dose. Second, we performed a meta-regression following[49] and as
434 performed in[50]. In brief, in both analyses, we log-transformed the RR obtained from the
435 studies and weighted the estimates according to the inverse of the 95% CI of the RR
436 estimate. We preferred to use RR rather than the number of cases[51] because there are
437 two studies in which RR estimates correct for participants' socio-demographic
438 covariates. The meta-regression allowed the inclusion of all doses (as a factor) into one
439 model and to account for estimates coming from the same studies by having the study
440 identity as a random intercept. To account for the fact that two studies were carried out
441 in the same population, we repeated the meta-regression by including the population as
442 a random intercept, which gave consistent results. We performed the meta-regression
443 in R v. 4.2.0[52] with the function 'brm' from the package 'brms'[53] using flat uninformative
444 priors with 100,000 iterations, 20,000 burn-ins, and a thinning of 40. Model residuals
445 fulfilled all assumptions as checked with the function 'createDHARMA' of the package
446 'DHARMa'[54]. Meta-analyses usually control the heterogeneity between studies and, most
447 importantly, for publication bias[49], but given the low number of studies and sample
448 sizes, this was not possible here.
449
450 *Simulation: Model schematic*
451
452 We implemented an age-structured model of pertussis transmission, extending a
453 previous model empirically validated on data from Massachusetts, USA[4,27]. In brief, the
454 model is based on the Susceptible-Exposed-Infected-Recovery (SEIR, Fig. S1) model in
455 which pertussis vaccines can fail by (i) failure in "take" (primary vaccine failure) and (ii)
456 failure in duration (waning of vaccine protection)[55]. Based on immunological evidence
457 showing an immediate reduction in the antibody response to primary vaccination[21,22,35],
458 we assumed that blunting from maternal immunization increased the probability of
459 primary vaccine failure. Previous results in[4] found no evidence for failure in degree (or
460 leakiness, i.e., when vaccine-induced protection is imperfect and vaccinees remain
461 susceptible to infection, but at a lower degree than unvaccinated individuals), and hence
462 we ignored this possibility.
463
464 The model is designed such that we follow individuals grouped according to their
465 immunization history. For each immunization, individuals can go to either of three

466 compartments: one for successful immunization, one for failed immunization, and one
467 for immunization not received (Fig. S1). These three possible paths or compartments
468 start from their mother's immunization status during pregnancy, followed by an infant
469 immunization schedule that resembles that of the empirical studies in Table S1: the
470 infant's primary immunization occurs at the age of three months, and an infant booster
471 at the age of 1.5 years. Hence, newborns can be born in three possible compartments:
472 from vaccinated mothers whose immunization succeeded, mothers whose
473 immunization failed (i.e., who received the vaccine but whose infant remained
474 unprotected), or unvaccinated mothers. We model maternal immunization by
475 transferring a fraction of newborns to a protected class. Maternal immunization in itself
476 is not modeled; hence our model does not specify at which stage of pregnancy maternal
477 immunization occurs. The assumed high effectiveness of maternal immunization
478 implies that it occurred at a timing consistent with that used in the studies in Table S1
479 and in the empirical studies of the systematic review, i.e., during the second or third
480 trimester of pregnancy and at least one week before giving birth.
481
482 Each of the three compartments is followed by a compartment for successful primary
483 infant immunization (Fig. S1) and a compartment for failed primary infant
484 immunization, thereby becoming susceptible (Fig. S1), or no immunization thereby also
485 becoming susceptible. Following the first booster, these susceptibles become
486 immunized again at an effectiveness of 96%, with a subsequent waning rate of vaccine
487 protection of 0.011 yr^{-1} (Table S3). For simplicity, as in earlier modeling studies[4] , we
488 model the infant primary immunization as one event and we do not consider the
489 gradual effect of multiple vaccine doses.
490
491 *Model parametrization*
492
493 Parametrization of the base model
494 Our model is based on[4], which was fitted to pertussis incidence data from
495 Massachusetts to identify the model parameters that best matched the data. Hence, for
496 the parameters consistent between both models, we used the estimates from[4] (Table
497 S3), but note that the sensitivity analyses explained below and shown in the
498 supplementary information create conditions that represent other populations.

By adding maternal immunization to this model, we also added three new parameters. The first parameter is maternal immunization coverage, for which we use a baseline of 70%, consistent with the empirical estimates a few years after the rollout of maternal immunization (Table S1). The second parameter is the duration of maternally derived immunity, for which, there are no empirical estimates. One proxy is the half-life of maternal antibodies, which ranges between 29 and 36 days[56,57], suggesting that the duration of maternally-derived immunity is short. However, because of the absence of definite correlates of protection[45–47], the correspondence between the waning rate of maternal antibodies and that of maternal immunity is unknown. For example, if both waning rates are assumed equal and without the transfer of new maternal antibodies, e.g., through breastfeeding, according to our model the effectiveness of maternal immunization in the first two months after birth would be close to 50% (Fig. S1). This is in contrast with the estimated effectiveness of maternal immunization in that age class, which ranged from 78% ([15] 95% CI: 48–90) to 93% ([12] 95% CI: 81–97). Thus, in our model, we calibrated the average duration of maternal protection to reach these empirical estimates of vaccine effectiveness and hence we show results with an average duration of 8.7 months (Table S3, Fig. S2). The third parameter is the blunting of infant immune protection, defined as the relative reduction in the effectiveness of the primary series in infants born to vaccinated mothers (compared to infants born to unvaccinated mothers). There are no empirical estimates of the degree of blunting of infant protection following maternal immunization or how changes in IgG titers translate into changes in protection. When infants receive their primary immunization, the antibody concentrations of infants from vaccinated mothers are 30% to 60% lower compared to those from unvaccinated mothers[21,22]. To best match the empirical estimates of the relative risk of pertussis, we chose a decrease in the effectiveness of primary immunization from 0% (i.e., no blunting) to 20%. Formally, the blunting paramet (1) modeled as a relative reduction in the initial effectiveness of infant immunization ε, resulting in a blunted effectiveness $\bar{\varepsilon} = \varepsilon(1 - b_1)$.

Sensitivity analyses

We checked the sensitivity of our results to nine model changes:

531 (i) maternal immunization coverage, changed from a baseline value of 70% to
532 50% and to 90% (Fig. S5, S6), which is the range represented in Table S1;
533 (ii) infant immunization coverage, changed from a baseline value of 90% to 70%
534 and 80% (Fig. S7, S8);
535 (iii) the average duration of maternal protection changed from a baseline value of
536 8.7 months to 4 months and 1 year (Fig. S9, S10);
537 (iv) the start of primary immunization, changed from a baseline value of 3
538 months to 2, 4, and 9 months (Fig. S11, S12);
539 (v) different social contact matrices, with that of the UK as baseline (in Figs. 4
540 and 5) and changed to those in 7 other European countries as described
541 in[58,59] (Fig. S13-S18). A more detailed age-specific contact matrix is available
542 for the UK[60], but not for other countries, and hence we used an age structure
543 that is consistent across countries;
544 (vi) starting the maternal immunization program 60 years after the rollout of
545 primary immunization, instead of 100 years. This reflects an introduction of
546 maternal immunization during a honeymoon-mediated pertussis resurgence,
547 as was the case in many countries (Fig. S19, S20);
548 (vii) blunting the effectiveness of the infant primary immunization up to 60% (Fig.
549 S21, S22), instead of the baseline range of 0% to 20%;
550 (viii) ±50% variations in the basic reproduction number, to model different
551 transmission levels in a range of populations (Fig. S23, S24);
552 (ix) the impact of the COVID-19 pandemic, modeled as a 3- to 9-month period
553 associated with lower vaccine coverage (20% reduction) and lower
554 transmission (20%, 50%, or 70% reduction, as a result of social distancing
555 measures, Fig. S25-S34). This sensitivity analysis is motivated by the
556 observation that COVID-19-associated social distancing measures
557 substantially decreased pertussis incidence[61,62]. To model NPIs during the
558 COVID-19 pandemic, we followed the approach from a previous study which
559 reduced the transmission between 20% and 70% for a duration of 3 months
560 and 9 months[63]. We obtained estimates of the changes in immunization
561 coverage during the COVID-19 pandemic from three empirical studies[64–66]. In
562 our model, we introduced these changes 8 years after the rollout of the
563 maternal immunization program because that matches the 8-year lag

between the first maternal immunization programs and the COVID-19 NPIs in most countries.

Estimation of relative risk of infection following maternal immunization

To connect the model outputs with the empirical estimates of relative risk (RR)[13,14,16,17], we calculated the risk of contracting pertussis in infants born to vaccinated mothers relative to that of infants born to unvaccinated mothers using the same approach as in[13,17]. These studies used the screening method following[67], in which the RR is estimated as:

$$RR = \frac{PCV}{(1 - PCV)} \cdot \frac{(1 - PPV)}{PPV} \tag{2}$$

where PCV (proportion of cases vaccinated) is the proportion of cases in vaccinated infants born to vaccinated mothers among all cases in infants vaccinated, and PPV is the proportion of the population vaccinated, here equal to the vaccine coverage of maternal immunization. We validated the RR estimates of the simulations by setting the half-life of maternally derived protection to infinity, which resulted in an RR of 0.05 in newborns and matched the initial 95% effectiveness of maternal immunization against pertussis in unvaccinated newborns fixed in the simulations (Fig. S2, Table S3). Hence, while the screening method may have several limitations in real-world settings[68], it provided reliable estimates of vaccine effectiveness in the context of our model.

Numerical implementation

We represented the process model as a continuous-time Markov process, approximated via the tau-leap algorithm[69] with a fixed time step of 1 day. To compare the model outputs to empirical estimates, we also added an observation model for the RR. This was done by sampling the number of vaccinated cases born to vaccinated mothers from a Binomial distribution with probability PCV and size equal to the number of cases described in the empirical studies at the third dose (Table S1). The model was implemented and simulated using the 'pomp' package v. 4.4.3.0[70], operating in R v. 4.2.0[52].

Data Availability

595 This manuscript does not contain any data

596

597 **Code Availability**

598 All R scripts are freely available via Edmond, the Open Data Repository of the Max
599 Planck Society[72].

600

601 **References**

602 1. Kilgore, P. E., Salim, A. M., Zervos, M. J. & Schmitt, H. J. Pertussis: Microbiology, Disease,
603 Treatment, and Prevention. *Clin. Microbiol. Rev.* **29**, 449–486 (2016).

604 2. Rohani, P. & Scarpino, S. V. *Pertussis: Epidemiology, Immunology & Evolution*. (Oxford
605 University Press, Oxford, 2019).

606 3. Amirthalingam, G., Gupta, S. & Campbell, H. Pertussis immunisation and control in England
607 and Wales, 1957 to 2012: a historical review. *Euro Surveill.* **18**, ii=20587 (2013).

608 4. Domenech de Cellès, M., Magpantay, F. M. G., King, A. A. & Rohani, P. The impact of past
609 vaccination coverage and immunity on pertussis resurgence. *Sci. Transl. Med.* **10**, eaaj1748
610 (2018).

611 5. Domenech de Cellès, M., Magpantay, F. M. G., King, A. A. & Rohani, P. The pertussis enigma:
612 reconciling epidemiology, immunology and evolution. *Proc. Biol. Sci. B* **283**, 20152309
613 (2016).

614 6. Kandeil, W. *et al.* A systematic review of the burden of pertussis disease in infants and the
615 effectiveness of maternal immunization against pertussis. *Expert Rev. Vaccines* **19**, 621–638
616 (2020).

617 7. Mbayei, S. A. *et al.* Severe Pertussis Infections in the United States, 2011–2015. *Clin. Infect.*
618 *Dis.* **69**, 218–226 (2019).

619 8. Quinn, H. E. *et al.* Pertussis disease and antenatal vaccine effectiveness in Australian
620 children. *Pediatr. Infect. Dis. J.* **41**, 180–185 (2022).

621 9. World Health Organization. Pertussis vaccines: WHO position paper – August 2015. (2015).

622 10. Abu-Raya, B. *et al.* Global perspectives on immunization during pregnancy and priorities for

623 future research and development: an international consensus statement. *Front. Immunol.*
624 **11**, 1282 (2020).
625 11. Amirthalingam, G. *et al.* Effectiveness of maternal pertussis vaccination in England: an
626 observational study. *Lancet* **384**, 1521–1528 (2014).
627 12. Dabrera, G. *et al.* A case-control study to estimate the effectiveness of maternal pertussis
628 vaccination in protecting newborn infants in England and Wales, 2012–2013. *Clin. Infect.*
629 *Dis.* **60**, 333–337 (2015).
630 13. Amirthalingam, G. *et al.* Sustained effectiveness of the maternal pertussis immunization
631 program in England 3 years following introduction. *Clin. Infect. Dis.* **63**, S236–S243 (2016).
632 14. Baxter, R., Bartlett, J., Fireman, B., Lewis, E. & Klein, N. P. Effectiveness of vaccination during
633 pregnancy to prevent infant pertussis. *Pediatrics* **139**, e20164091 (2017).
634 15. Skoff, T. H. *et al.* Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis
635 Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control
636 Evaluation. *Clin. Infect. Dis.* **65**, 1977–1983 (2017).
637 16. Rowe, S. L. *et al.* Maternal vaccination and infant influenza and pertussis. *Pediatrics* **148**,
638 e2021051076 (2021).
639 17. Amirthalingam, G. *et al.* Optimization of Timing of Maternal Pertussis Immunization From 6
640 Years of Postimplementation Surveillance Data in England. *Clin. Infect. Dis.* **8**, e1129–e1139
641 (2023).
642 18. Albrecht, P., Ennis F. A., Saltzman, E. J. & Krugman, S. Persistence of maternal antibody in
643 infants beyond 12 months: mechanism of measles vaccine failure. *J. Pediatr.* **91**, 715–717
644 (1977).
645 19. Bento, A. I., King, A. A. & Rohani, P. Maternal pertussis immunisation: clinical gains and
646 epidemiological legacy. *Euro Surveill.* **22**, 30510 (2017).
647 20. Leuridan, E. Pertussis vaccination in pregnancy: State of the art. *Vaccine* **35**, 4453–4456
648 (2017).
649 21. Barug, D. *et al.* Maternal pertussis vaccination and its effects on the immune response of

650 infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised
651 controlled trial. *Lancet Infect. Dis.* **19**, 392–401 (2019).
652 22. Abu-Raya, B. *et al.* The effect of Tetanus-Diphtheria-Acellular-Pertussis immunization
653 during pregnancy on infant antibody responses: individual-participant data meta-analysis.
654 *Front. Immunol.* **12**, 689394 (2021).
655 23. Jones, C. E. *et al.* A phase IV, multi-centre, randomized clinical trial comparing two
656 pertussis-containing vaccines in pregnant women in England and vaccine responses in
657 their infants. *BMC Med.* **19**, 138 (2021).
658 24. Sapuan, S. *et al.* An observational, cohort, multi-centre, open label phase IV extension study
659 comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were
660 randomised to one of two pertussis-containing vaccines or received no pertussis-
661 containing vaccine in pregnancy in England. *Vaccine* **40**, 7050–7056 (2022).
662 25. Caboré, R. N. *et al.* Influence of maternal vaccination against diphtheria, tetanus, and
663 pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in
664 Belgium. *Virulence* **8**, 1245–1254 (2017).
665 26. Zimmermann, P. *et al.* The effect of maternal immunisation during pregnancy on infant
666 vaccine responses. *EClinicalMedicine* **13**, 21–30 (2019).
667 27. Domenech de Cellès, M., Rohani, P. & King, A. A. Duration of Immunity and Effectiveness of
668 Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. *JAMA Pediatr.* **173**, 588–594
669 (2019).
670 28. Kampmann, B. *et al.* Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in
671 Infants. *N. Engl. J. Med.* **388**, 1451–1464 (2023).
672 29. Venkatesan, P. First RSV vaccine approvals. *Lancet Microbe* **4**, e577 (2023).
673 30. Omer, S. B. Maternal Immunization. *N. Engl. J. Med.* **376**, 1256–1267 (2017).
674 31. Halasa, N. B. *et al.* Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine
675 During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months
676 - 17 States, July 2021-January 2022. *MMWR Morb. Mortal. Wkly. Rep.* **71**, 264–270 (2022).

677 32. Etti, M. *et al.* Maternal vaccination: a review of current evidence and recommendations. *Am.*
678 *J. Obstet. Gynecol.* **226**, 459–474 (2022).
679 33. Gans, H. A. *et al.* Deficiency of the Humoral Immune Response to Measles Vaccine in Infants
680 Immunized at Age 6 Months. *JAMA* **280**, 527–532 (1998).
681 34. Mawa, P. A. *et al.* The impact of maternal infection with Mycobacterium tuberculosis on the
682 infant response to bacille Calmette–Guérin immunization. *Philos. Trans. R. Soc. Lond. B Biol.*
683 *Sci.* **3017**, 20140137 (2015).
684 35. Voysey, M. *et al.* The influence of maternally derived antibody and infant age at vaccination
685 on infant vaccine responses: an individual participant meta-analysis. *JAMA Pediatr.* **17**,
686 637–646 (2017).
687 36. Grassly, N. C. *et al.* Effect of maternal immunisation with multivalent vaccines containing
688 inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-
689 centre randomised trial. *Vaccine* **41**, 1299–1302 (2023).
690 37. Abu-Raya, B. *et al.* Factors affecting antibody responses to immunizations in infants born to
691 women immunized against pertussis in pregnancy and unimmunized women: Individual-
692 Participant Data Meta-analysis. *Vaccine* **39**, 6545–6552 (2021).
693 38. Perkins, T. A. & Tran, Q. M. Timing is everything when it comes to pertussis vaccination.
694 *Lancet Infect. Dis.* **22**, 158–159 (2022).
695 39. Paireau, J. *et al.* Impact of vaccine schedule change on pertussis epidemiology in France: a
696 modelling and serological study. *Lancet Infect. Dis.* **22**, 265–273 (2022).
697 40. Rijksinstituut_Voor_Volksgezondheid_en_Milieu. Rijksinstituut voor Volksgezondheid en
698 Milieu. *Dutch National Immunisation Programme.*
699 https://rijksvaccinatieprogramma.nl/english (2021).
700 41. Riolo, M. A. & Rohani, P. Combating pertussis resurgence: One booster vaccination schedule
701 does not fit all. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E472–E477 (2015).
702 42. Bento, A. I. & Rohani, P. Forecasting Epidemiological Consequences of Maternal
703 Immunization. *Clin. Infect. Dis.* **63**, S205–S212 (2016).

43. World Health Organization. *Measuring impact of streptococcus pneumoniae and haemophilus influenzae type b conjugate vaccination*. (2012).

44. Skoff, T. H., Deng, L., Bozio, C. H. & Hariri, S. US Infant Pertussis Incidence Trends Before and After Implementation of the Maternal Tetanus, Diphtheria, and Pertussis Vaccine. *JAMA Pediatr.* **177**, 395–400 (2023).

45. Van Rie, A., Wendelboe, A. M. & Englund, J. A. Role of maternal pertussis antibodies in infants. *Pediatr. Infect. Dis. J.* **24**, S62–S65 (2005).

46. Diavatopoulos, D. A. *et al.* PERISCOPE: road towards effective control of pertussis. *Lancet Infect. Dis.* **19**, e179–e186 (2019).

47. Chen, Z. *et al.* Evaluation of serum anti-pertussis toxin IgA antibodies for the diagnosis of Bordetella pertussis infection in young children. *J. Infect. Public Health* **16**, 1167–1173 (2023).

48. Eurostat. How many children were born in the EU in 2021? https://ec.europa.eu/eurostat/en/web/products-eurostat-news/w/ddn-20230309-1 (2023).

49. Nakagawa, S. & Santos, E. S. A. Methodological issues and advances in biological meta-analysis. *Evol. Ecol.* **26**, 1253–1274 (2012).

50. Kärkkäinen, T., Briga, M., Laaksonen, T. & Stier, A. Within-individual repeatability in telomere length: A meta-analysis in nonmammalian vertebrates. *Mol. Ecol.* **31**, 6339–6359 (2022).

51. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J. Stat. Softw.* **36**, 1–48 (2010).

52. R Core Team. *R: A Language and Environment for Statistical Computing*. https://www.R-project.org/ (2022).

53. Bürkner, P.-C. brms: An R Package for Bayesian Multilevel Models Using Stan. *J. Stat. Softw.* **80**, 1–28 (2017).

54. Hartig, F. DHARMa: Residual Diagnostics for Hierarchical (Multi-Level / Mixed) Regression

731 Models. R package version 0.4.6. http://florianhartig.github.io/DHARMa/ (2022).
732 55. McLean, A. R. & Blower, S. M. Imperfect vaccines and herd immunity to HIV. *Proc. R Soc B*
733 *Biol. Sci.* **253**, 9–13 (1993).
734 56. Healy, C. M. *et al.* Kinetics of maternal pertussis-specific antibodies in infants of mothers
735 vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy.
736 *Vaccine* **38**, 5955–5961 (2020).
737 57. Oguti, B. *et al.* The half-life of maternal transplacental antibodies against diphtheria,
738 tetanus, and pertussis in infants: an individual participant data meta-analysis. *Vaccine* **40**,
739 450–458 (2022).
740 58. Mossong, J. *et al.* Social contacts and mixing patterns relevant to the spread of infectious
741 diseases. *PLoS Med.* **5**, e74 (2008).
742 59. Béraud, G. *et al.* The French Connection: The First Large Population-Based Contact Survey
743 in France Relevant for the Spread of Infectious Diseases. *PLoS One* **10**, e0133203 (2015).
744 60. van Hoek, A. J. *et al.* The Social Life of Infants in the Context of Infectious Disease
745 Transmission; Social Contacts and Mixing Patterns of the Very Young. *PLoS ONE* **8**, e76180
746 (2013).
747 61. Tessier, E. *et al.* Impact of the COVID-19 pandemic on Bordetella pertussis infections in
748 England. *BMC Public Health* **22**, 405 (2022).
749 62. Reicherz, F., Golding, L., Lavoie, P. M. & Abu-Raya, B. Decay of anti-Bordetella pertussis
750 antibodies in women of childbearing age following COVID-19 non-pharmaceutical
751 measures. *Vaccine* **40**, 3746–3751 (2022).
752 63. Brett, T. S. & Rohani, P. Transmission dynamics reveal the impracticality of COVID-19 herd
753 immunity strategies. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 25897–25903 (2020).
754 64. Causey, K. *et al.* Estimating global and regional disruptions to routine childhood vaccine
755 coverage during the COVID-19 pandemic in 2020: a modelling study. *Lancet* **398**, 522–534
756 (2021).
757 65. Kim, S., Headley, T. Y. & Tozan, Y. Universal healthcare coverage and health service delivery

758 before and during the COVID-19 pandemic: A difference-in-difference study of childhood
759 immunization coverage from 195 countries. *PLoS Med.* **19**, e1004060 (2022).
760 66. Lai, X. *et al.* Estimating global and regional between-country inequality in routine childhood
761 vaccine coverage in 195 countries and territories from 2019 to 2021: a longitudinal study.
762 *EClinicalMedicine* **60**, 102042 (2023).
763 67. Farrington, C. P. Estimation of vaccine effectiveness using the screening method. *Int. J.*
764 *Epidemiol.* **22**, 742–746 (1993).
765 68. Minodier, L. *et al.* Influenza vaccine effectiveness: best practice and current limitations of
766 the screening method and their implications for the clinic. *Expert Rev. Vaccines* **13**, 1039–
767 1048 (2014).
768 69. He, D., Ionides, E. L. & King, A. A. Plug-and-play inference for disease dynamics: measles in
769 large and small populations as a case study. *J. R. Soc. Interface* **7**, 271–283 (2010).
770 70. King, A. A., Nguyen, D. & Ionides, E. L. Statistical Inference for Partially Observed Markov
771 Processes via the R Package pomp. *J. Stat. Softw.* **69**, 1–43 (2016).
772 71. Page, M. J. *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic
773 reviews. *BMJ* **372**, n71 (2021).
774 72. Briga M, Goult E, Brett TS, Rohani P, Domenech de Cellès M. Code for 'Maternal pertussis
775 immunization and the blunting of routine vaccine effectiveness: A meta-analysis and
776 modeling study.' Available at: https://doi.org/10.17617/3.PHDF21 (2023).

Acknowledgments

We thank the useful discussions with and feedback from Andrew Tredennick (University of Georgia, USA), Christian Gunning (University of Georgia, USA), Denis Macina (Sanofi Pasteur, France), Laurent Coudeville (Sanofi Pasteur, France), and Edward Thommes (Sanofi Pasteur, Canada). We thank Laura Barrero Guevara (Infectious Disease Epidemiology Group, Max Planck Institute for Infection Biology, Berlin, Germany) for useful feedback on the figures. MB, EG, MDC were funded by the Max Planck Society through funding awarded to MDC.

Author Contributions Statement

MB and MDC designed the model. MB performed the simulations. MB and MDC analyzed the model output. MB performed the systematic review and wrote the first version of the manuscript. MB and MDC designed the research. MDC supervised the analyses. MB, MDC, PR, TB, EG interpreted the results and made revisions to the paper.

Competing Interests Statement

Prof. Pejman Rohani received funding from Sanofi France for another separate project. The remaining authors declare no competing interests.

Tables

NA

Figure Legends/Captions

Fig. 1 Prisma flow chart, following[71], of the literature search for empirical estimates of the relative risk (RR) of contracting pertussis following maternal immunization in children who had received at least one dose of infant primary immunization.

Fig. 2 Overview of the results from empirical epidemiologic studies of the relative risk of contracting pertussis after 1–3 vaccine doses for primary immunization in infants from vaccinated mothers relative to those of unvaccinated mothers during infant primary immunization. The literature search protocol is shown in Fig. 1, and the data and sample sizes for each estimate are available in Table S1. The two lines for the UK 3-year study represent two estimates of maternal immunization coverage. Dots represent means and

error bars show 95% CI. References: Australia 2 yrs[16], California 6 yrs[14], UK 3 yrs[13], and UK 6 yrs[17]. Abbreviation yrs=years.

Fig. 3 Illustration of honeymoon effects and transient susceptible dynamics following the start of infant immunization (vertical dashed line at time = 0 years) and maternal immunization without blunting (vertical dashed line at time = 100 years) showing (A) pertussis incidence and (B) the fraction susceptible for each age class from one stochastic simulation.

Fig. 4 Model predictions of the consequences of maternal immunization and blunting for pertussis incidence in (A) unvaccinated newborns (aged 0–2 mo) and (B) vaccinated infants (aged 3–18 mo, after receipt of primary immunization). For this age class, during the transient phase after maternal immunization, pertussis incidence is at first mostly driven by (C) infants from unvaccinated mothers until (D) pertussis incidence is most abundant in infants from vaccinated mothers. Panel (D) is consistent with the PCV-term in the RR equation (see methods[67]). Solid lines show the median incidence of 100 simulations and shaded areas represent the 95% CI. Pertussis incidence before the start of the maternal immunization program is shown as a control, and variation in incidence between simulations is the result of demographic stochasticity. In this figure, all immunization coverages were set at 70%, which is close to the mean observed values in empirical studies (e.g., Table S1). Note the different y-axis between panels.

Fig. 5 Temporal dynamics of the risk of contracting pertussis in (A) unvaccinated newborns and (B, C) vaccinated infants from vaccinated mothers relative to those of unvaccinated mothers. (A, B) Solid lines show the median RR of 100 simulations and shaded areas show 95% CI resulting from demographic stochasticity across simulations. (C) Comparison between the results from model simulations (gradient red diamonds) and the empirical studies (colored dots). In panel (C), dots represent means and vertical lines show 95% CI for both data and simulations. Here, the 95% CI of the simulations emerge from both demographic stochasticity and observation uncertainty, resulting from the partial sampling of the population with the sample sizes (number of cases) matching those from empirical studies in Fig. 2 (Table S1).


Identification of studies via databases and registers
Identification
Records identified from:
Web of Science: 128
PubMed: 72
Scopus: 136
Total: 374
Duplicate records removed before screening: 146
Screening
Records screened: 228
Records excluded by human reading abstract: 159
Reports sought for retrieval: 69
Reports not retrieved: 0
Reports assessed for eligibility: 69
Reports excluded:
1. Reviews, commentaries, reports, or opinion papers without primary data (n=42)
2. No age-specific data during or after primary immunization (n=9)
3. Simulation study (n=3)
4. Data on primary doses pooled (n=2)
5. Study on vaccination coverage or incentive (n=3)
6. Protocol studies (n=2)
7. Antibody data but no incidence (n=2)
8. No laboratory-based diagnosis (n=1)
9. Cocooning study (n=1)
Included
Studies included in review: 4

842


Study
Australia 2yrs
California 6yrs
UK 3yrs
UK 6yrs
Weighted mean
Relative risk of pertussis
0
2
4
6
1
2
3
Dose of infant primary immunization

843


A
Incidence (per yr, per 100,000)
1000
100
10
−50
0
50
100
150
200
Time (years)
B
Age (years)
80
60
40
20
0
−50
0
50
100
150
200
Time (years)
Fraction susceptible
0.75
0.50
0.25

844

845


A
0–2 months – All infants
B
3–18 months – All infants
C
3–18 months
Infants from unvaccinated mothers
D
3–18 months
Infants from vaccinated mothers
Incidence (per yr, per 100,000)
Time since start of maternal immunization program (years)
Simulated blunting
0%
10%
20%

846


A
0–2 months
Relative risk of pertussis
0.25
0.20
0.15
0.10
0.05
0.00
1
5
10
25
50
75
Time since start maternal immunization program (years)
Simulated blunting
0%
10%
20%
B
3–18 months
Relative risk of pertussis
3
2
1
0
1
5
10
25
50
75
Time since start maternal immunization program (years)
C
3–18 months
Relative risk of pertussis
6
4
2
0
n=11
n=14
n=21
n=169
2
3
6
6
Time since start maternal immunization program (years)
Study
Australia
California
UK
UK
Simulated blunting
0%
10%
20%

847